

Figure S1. The safe administration concentrations of the resveratrol

(a) The CCK8 assay was used to determine the safe administration concentrations of the resveratrol, and the data from the experiments were plotted to extrapolate the CC50 values (n=6).




Figure S2. Antiviral activity of resveratrol against RSV in Hep-2 cells and BEAS-2B cells

(A) The CCK8 assay was used to determine the safe administration concentrations of the resveratrol in Hep-2 cells (n=6). (B) RSV N protein expression was detected to determine RSV infection by Quantitative Real-time PCR, (n=4). (C) The CCK8 assay was used to determine the safe administration concentrations of the resveratrol in BEAS-2B cells (n=6). (D) RSV N protein expression was detected to determine RSV infection by Quantitative Real-time PCR, (n=4). Data are represented as mean \pm SEM. * $P < 0.05$, ** $P < 0.01$, *** $P < 0.001$.




Figure S3. Antiviral activity of resveratrol against RSV detected by Flow cytometry

(A and B) RSV G protein expression was detected to determine RSV infection by Flow cytometry (n=4). Data are represented as mean \pm SEM. * $P < 0.05$, ** $P < 0.01$, *** $P < 0.001$.




Figure S4. Time of addition experiment of viral titration on cell culture and immunofluorescence

(A) Time-of-addition assay, and the schematic procedure. (B) Determination of viral titers with TCID50 assay (n=3). (C and D) RSV G protein expression was detected to determine RSV infection by immunofluorescence. Data are represented as mean \pm SEM. *P<0.05, **P<0.01, ***P<0.001.




Figure S5. Resveratrol administration only reduced infected cells in alveoli and not in bronchus

(A, B and C) Immunohistochemistry of RSV F protein in mouse lung tissue (n=3). Data are represented as mean \pm SEM. * $P < 0.05$, ** $P < 0.01$, *** $P < 0.001$.